Development of new antidepressants.

Jan 1, 1997The Journal of clinical psychiatry

Creating New Medicines for Depression

AI simplified

Abstract

A large number of novel antidepressants are currently undergoing clinical evaluation with dual mechanisms of action on various neurotransmitter receptors.

  • Many antidepressants target multiple neurotransmitter receptors, including serotonin and noradrenergic systems.
  • Mirtazapine exemplifies this dual action by disinhibiting serotonin and norepinephrine neurotransmission.
  • Mirtazapine's antagonistic properties at serotonin-2 and serotonin-3 receptors may reduce side effects associated with traditional SSRIs.
  • The concept of 'designer polypharmacy' aims to combine pharmacologic principles to enhance effectiveness and tolerability of new antidepressants.

AI simplified

what lands in your inbox each week:

  • πŸ“š7 fresh studies
  • πŸ“plain-language summaries
  • βœ…direct links to original studies
  • πŸ…top journal indicators
  • πŸ“…weekly delivery
  • πŸ§˜β€β™‚οΈalways free